Clear Cell Adenocarcinoma — Trials

Clear Cell Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

362 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 150
Recruiting: 79
Ph III recruiting: 9
Growth YoY: −15.8%
Industry share: 24%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 301–350 of 362 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00807768	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer	unknown	Phase 3	601	Gynecologic Oncology GroupNETWORK	2	Mar 20, 2019	clinicaltrials
NCT01489371	EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	completed	Phase 1	16	Gynecologic Oncology GroupNETWORK	1